Island Pharmaceuticals Limited (ASX: ILA) is advancing its antiviral strategy through the clinical development of Galidesivir, a broad-spectrum antiviral targeting high-consequence viral threats, including Marburg and Ebola. The program is positioned within a global biosecurity and public health framework, with regulatory engagement centred on the United States Food and Drug Administration (FDA) and potential inclusion in government stockpiles.

IRIS Metals Limited (ASX: IR1) has reported high-grade rubidium assay results from its 2023 and 2024 drilling programs at the Beecher Project, located in the southern Black Hills of South Dakota, USA (Figure 1). The results confirm a significant rubidium discovery alongside the project’s established lithium resource, further positioning Beecher as a multi-commodity critical minerals asset in a mining-friendly U.S. jurisdiction.

AuMEGA Metals Ltd (ASX: AAM) has reported the results of its 2025 surficial till geochemistry and geological mapping program at the Bunker Hill Project, located within the Company’s 110-kilometre district-scale landholding along the Cape Ray Shear Zone (CRSZ) in southwestern Newfoundland, Canada. The work provides a materially improved understanding of structural controls, system scale, and target prioritisation across Bunker Hill, reinforcing the project’s underexplored pote

BCAL Diagnostics is transitioning from a long-standing research-led organisation into a commercial early cancer diagnostics company, with laboratory operations based in Sydney and expanding national reach across Australia. The Company’s FY25 AGM and its 9 December 2025 ASX announcement collectively outline a business now focused on scaling commercial adoption following the launch of its first diagnostic product and the upcoming national rollout of additional early-detection t

The Australian healthcare sector continues to attract investor attention as companies progress from early development into clinical validation, regulatory approval, and commercial execution. This ASX Companies Snapshot & Market Position provides a concise, side-by-side overview of selected ASX-listed healthcare companies, outlining what each business does, where it sits within the market, and how it is currently positioned from a market capitalisation and execution perspectiv

Adisyn Ltd (ASX: AI1) is advancing a graphene-based semiconductor technology platform through its wholly owned subsidiary, 2D Generation (2DG), supported by international research collaborations across Israel, Europe, and the United States. The Company’s core development work focuses on low-temperature graphene deposition processes designed for compatibility with existing semiconductor manufacturing environments.

Proteomics International Laboratories Ltd (ASX: PIQ), based in Perth, Western Australia, has announced a major intellectual property milestone with the granting of a United States patent for its PromarkerEso diagnostic test (Figure 1). The patent strengthens the Company’s position in the world’s largest healthcare market and supports the commercialisation pathway for a first-in-class blood test targeting esophageal adenocarcinoma (EAC), a cancer with poor survival outcomes wh

Encounter Resources Limited (ASX: ENR) has reported continued success from aircore drilling at the Green Prospect, part of the Aileron Project in the West Arunta region of Western Australia (Figure 1). Recent drilling has confirmed the extension of shallow, high-grade niobium mineralisation east of the existing Green Mineral Resource Estimate (MRE), reinforcing the scale and continuity of this emerging carbonatite-hosted niobium system.

Critical Resources Limited (ASX: CRR) has delivered its maiden drilling update from the Amoco Gold–Antimony Project, located in the highly prospective New England Fold Belt, approximately 19 km south-east of the Hillgrove Antimony-Gold Project and 14 km east of Koonenberry Gold’s Enmore Project. ). The announcement confirms that Amoco hosts a substantial mineralised orogenic system.

Viking Mines Limited (ASX: VKA) has announced the acquisition of a high-grade, production-proven tungsten portfolio in Nevada, USA, a Tier-1 mining jurisdiction (Figure 1). The transaction provides Viking with 100% exposure to six historical tungsten projects located in close proximity to strategic US defence infrastructure, positioning the Company within a critical minerals supply chain at a time of heightened geopolitical urgency.